APTEVO THERAPEUTICS INC
APVONASDAQTrading Snapshot
- Day Range
- $1.85 – $1.90
- 52-Week Range
- $1.37 – $35.64
- Volume
- $1.66B
- Avg Volume
- $1.16B
- Shares Outstanding
- 2.2M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $387,857
- Last Q Revenue
- $103,745
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-22.07
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +24531.7%
Why Investors Own APVO
- ✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APTEVO THERAPEUTICS INC
APVO
StockOtter · stockotter.spaceAbout APTEVO THERAPEUTICS INC
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enablin
Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report)'s share price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $3.22 and traded as low as $1.73. Aptev
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 m
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-st
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances AP
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, to